Identification of FtfL as a novel target of berberine in intestinal bacteria
Abstract Background Berberine (BBR) is a commonly used anti-intestinal inflammation drug, and its anti-cancer activity has been found recently. BBR can intervene and control malignant colorectal cancer (CRC) through intestinal microbes, but the direct molecular target and related mechanism are uncle...
Main Authors: | Jinci Yan, Chengli Fang, Gaohua Yang, Jianxu Li, Yanqiang Liu, Lu Zhang, Pengjie Yang, Jingyuan Fang, Yang Gu, Yu Zhang, Weihong Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-12-01
|
Series: | BMC Biology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12915-023-01778-w |
Similar Items
-
Essential role of proline synthesis and the one-carbon metabolism pathways for systemic virulence of Streptococcus pneumoniae
by: Elisa Ramos-Sevillano, et al.
Published: (2024-11-01) -
Application of a Colorimetric Assay to Identify Putative Ribofuranosylaminobenzene 5'-Phosphate Synthase Genes Expressed with Activity in <it>Escherichia coli</it>
by: Bechard Matthew E., et al.
Published: (2003-01-01) -
Berberine attenuate staphylococcal enterotoxin B-mediated acute liver injury via regulating HDAC expression
by: Jiying Du, et al.
Published: (2018-10-01) -
Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus
by: Qiongyao He, et al.
Published: (2022-11-01) -
Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients
by: Chongming Wu, et al.
Published: (2022-03-01)